Observational Study of LUMRYZ in Narcolepsy (REFRESH)
A Prospective, Multicenter, Observational Study of LUMRYZ Used in Clinical Practice for the Treatment of Narcolepsy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Avadel Medical Information
- Phone Number: 888-828-2335
- Email: medinfo@avadel.com
Study Contact Backup
- Name: Gretchen Richards, MS
- Phone Number: 636-237-7167
- Email: grichards@avadel.com
Study Locations
-
-
Florida
-
Bradenton, Florida, United States, 34209
- Jeremy D McConnell, MD PA
-
-
Michigan
-
East Lansing, Michigan, United States, 48823
- Comprehensive Sleep Center
-
-
New Jersey
-
Middletown, New Jersey, United States, 07748
- Patient First MD
-
-
New York
-
East Syracuse, New York, United States, 13057
- Ghaly Sleep Management Services
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Medical Center
-
Dublin, Ohio, United States, 43017
- Ohio Sleep Medicine Institute
-
-
Pennsylvania
-
Abington, Pennsylvania, United States, 19001
- Abington Neurological Associates
-
Wynnewood, Pennsylvania, United States, 19096
- Pulmonology Associates, Inc.
-
Wyomissing, Pennsylvania, United States, 19610
- Respiratory Specialists
-
-
South Carolina
-
Columbia, South Carolina, United States, 29201
- Bogan Sleep Consultants
-
-
Texas
-
Sugar Land, Texas, United States, 77478
- Tricoastal Narcolepsy and Sleep Disorder Center
-
Tomball, Texas, United States, 77375
- Northwest Houston Neurology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults with narcolepsy
- Oxybate naive or prior treatment with twice-nightly oxybate
- Access to smart phone, tablet or laptop with reliable internet connection
- Able to read/understand English
- Written informed consent and ability to comply with schedule
Exclusion Criteria:
- Already using LUMRYZ
- Clinical or mental health condition excluded by LUMRYZ label
- Any other condition/situation that would adversely impact participation
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients Starting LUMRYZ
The cohort is comprised of patients prescribed LUMRYZ in clinical practice.
All dosing decisions are made by the clinician.
|
Prescribed for narcolepsy in accordance with product label.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Epworth Sleepiness Scale
Time Frame: Baseline to Month 4
|
Change from the first visit (baseline), prior to start of LUMRYZ, to Month 4; measure of sleepiness with total possible score of 0-24 (higher score equivalent to higher sleepiness)
|
Baseline to Month 4
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Narcolepsy Severity Scale
Time Frame: Baseline to Month 4
|
Change from the first visit (baseline), prior to start of LUMRYZ, to Month 4; measure of narcolepsy symptom frequency and impact on daily life with total possible score from 0-57 (higher score indicates more frequent and severe symptoms)
|
Baseline to Month 4
|
|
Sheehan Disability Scale
Time Frame: Baseline to Month 4
|
Change from the first visit (baseline), prior to start of LUMRYZ, to Month 4; measure of disruption to normal activities using a 0-10 scale, along with the number of days missed and/or underproductive at work/school
|
Baseline to Month 4
|
|
Patient Global Impression of Change
Time Frame: Month 4
|
Measure of improvement at Month 4 using a scale of 1 (very much improved) to 7 (very much worse); scored by patient
|
Month 4
|
|
Clinical Global Impression of Change
Time Frame: Month 4
|
Measure of improvement at Month 4 using a scale of 1 (very much improved) to 7 (very much worse); scored by clinician
|
Month 4
|
|
Adverse Reactions
Time Frame: Month 1, Month 2, Month 3, Month 4
|
Clinician-directed interview for common adverse reactions
|
Month 1, Month 2, Month 3, Month 4
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PMLUM-2402
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.